E Ink Announces Digital Paper Device Loaner Program for Smart Hospital/Healthcare

BILLERICA, Mass.–(BUSINESS WIRE)–E Ink Holdings, “E Ink” (8069.TW), the leading innovator of electronic ink technology, today announced a digital paper device loaner program for Smart Hospitals.

As hospitals consider how to improve the patient experience, digitization has become a much higher priority. However, hospitals are looking for a solution that enhances the patient’s and health care professional’s communication, but contains no emissive light pollution and no blue light emissions, which can hinder the patient healing and sleep cycles. In addition, devices using E Ink’s Digital Paper can be installed in minutes with significantly lower installation costs.

Benefits of E Ink’s Digital Paper display solutions:

  • Low power consumption – can be powered by batteries/PoE
  • Low Requirement for data bandwidth
  • Connect to EHR/EMR to show HIPAA compliant, “always-on” information
  • Easy and low-cost installation
  • No light pollution

“E Ink is very excited to launch the Device Loaner Program with our partners, Avalue Technology and DCI Healthcare Technology,” said Paul Apen, CSO of E Ink. “This program allows hospitals to easily deploy a test pilot in their facilities and evaluate the technology and its impact on their operations and patient/clinician experience.”

The number of devices for the program is customized by the needs of the installation, and are available for up to six months, depending on deployment needs. The program includes the following devices:

  • 7.8″ Patient Room Door Sign / Patient Care Sign
  • 42″ Patient Communication Board
  • Software to connect devices to facility EHR/EMR (as needed)

Learn more about the loaner program at http://go.eink.com/hospital-loaner-program.

About E Ink

E Ink Holdings Inc. (8069.TWO), based on technology from MIT’s Media Lab, has transformed and defined the eReader market, enabling a new multi-billion dollar market in less than 10 years. E Ink’s low power products are ideal for IoT applications ranging from retail, home, hospital, transportation and more, enabling customers to put displays in locations previously impossible. The Company’s corporate philosophy aims to deliver revolutionary products, user experiences and environmental benefits through advanced technology development. This vision has led to its continuous investments in the field of ePaper displays as well as expanding the use of its technologies into a number of other markets and applications including smart packaging and fashion. Its Electrophoretic Display products make it the worldwide leader for ePaper. Its Fringe Field Switching (FFS) technologies are a standard for high-end LCD displays and have been licensed to all major liquid crystal display makers in the world. Listed in Taiwan’s Taipei Exchange (TPEx) and the Luxembourg market, E Ink Holdings is now the world’s largest supplier of ePaper displays. For more information please visit www.eink.com.

Contacts

Racepoint Global

Anna Halstead, 617-624-3492

eink@racepointglobal.com

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

5 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

8 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

8 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

8 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

8 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

8 hours ago